O-001An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. (2nd July 2019) - Reni, M; Riess, H; O'Reilly, E; Santoro, A; Park, J; Bekaii-Saab, T; Tempero, M; Shan, Y; Macarulla, T; Cutsem, E Van; Noel, M; Berlin, J; et al.